[바이오 단신] Microbiotics attracts Series B investment worth 15 billion won

Microbiotics CI. (Photo provided by Microbiotics)”/>

▲Microbiotics CI. (Photo provided by Microbiotics)

Microbiotics attracts Series B investment worth 15 billion won

Microbiotics, a company specializing in bacteriophage new drug development, succeeded in attracting Series B investment worth 15 billion won. With this investment, the cumulative investment amount is 24 billion won. Microbiotics plans to use this investment to initiate Korea’s first bacteriophage clinical trial and accelerate the development of a follow-up pipeline.

Microbiotics is a bacteriophage treatment company that targets diseases caused by superbacteria (multi-drug resistant bacteria). It has a platform for developing phage therapeutics, including a bacteriophage library panel targeting clinically isolated multidrug-resistant bacteria, an in silico module, and a cGMP-level phage production facility.

RP Bio ranks first in sales of health functional food ‘Vitamin D’ for 3 consecutive years

Rpbio announced on the 21st that it has ranked first in sales for three consecutive years in the vitamin D category of domestic health functional foods, recording an average market share of 44%. According to the Ministry of Food and Drug Safety’s ‘Production Performance of Food, etc.’ report, from 2021 to 2023, Rpbio ranked first in sales among domestic companies producing health functional food vitamin D.

Vitamin D is a nutrient that plays an important role in strengthening immunity and bone health, and as interest in health increases, demand from consumers is rapidly increasing. Rpbio’s cumulative sales of vitamin D over the past three years were KRW 14.3 billion, three times more than its competitors. The market share was 42% in 2023, 45% in 2022, and 44% in 2021, ranking first for three consecutive years.

Bioneer signs an exclusive CosmeRNA supply agreement with Brazil’s Med Solutions Ltda.

Bioneer signed a strategic partnership with Med Solutions Ltda., a Brazilian medical device distribution company, and completed an exclusive supply agreement for ‘CosmeRNA ARI’, a hair loss care product. Through this contract, CosmeRNA will be supplied through a network of approximately 10,000 hospitals across Brazil.

According to the contract, Med Solutions Ltda. must fulfill the minimum order amount of more than USD 11.34 million (approximately KRW 15.5 billion) to meet the sales target of CosmeRNA products for three years to maintain exclusive supply rights. Through this, Bioneer is further strengthening its position in the Brazilian hair loss market and is expecting stable market entry and continued growth.

CHA Vaccine Research Institute presents research at the International Society of Vaccines (ISV) 2024

CHA Vaccine Research Institute, an affiliate of CHA Biotech, participates in the ‘International Society for Vaccine Congress (ISV)’ and announces the latest research results. The research results on respiratory infectious disease vaccine strategies using the next-generation immune enhancement platform ‘L-pampo™’ independently developed at this conference will be introduced through a poster presentation.

This study shows that El-Fampo™ can strengthen the immune response of influenza and COVID-19 vaccines, and that it is also effective in mucosal vaccines such as nasal or sublingual (under the tongue) administration rather than intramuscular injection. In an influenza vaccine study, the result of nasal administration of a vaccine combining antigen and L-Fampo™ produced a higher level of neutralizing antibodies compared to ‘FluMist®’, a currently commercially available nasal influenza vaccine, and also showed a strong mucosal immune response.

Mucosal immunity vaccines can be more effective against mutant viruses by inducing a strong cellular immune response as well as neutralizing antibodies. Additionally, it can be easily administered even in areas with poor medical infrastructure as it is a non-invasive method rather than an injection.